Last updated: February 23, 2026
What is the drug identified by NDC 72205-0146?
The National Drug Code (NDC) 72205-0146 refers to Immunoglobulin Intravenous (Human), marketed under brand names such as Gammagard and others. It is used for immunodeficiency, autoimmune diseases, and certain neurological conditions. This class of drugs involves plasma-derived human immunoglobulins, with significant demand driven by treatment of primary immunodeficiencies and off-label uses.
Market size and demand drivers
Current Market Size
As of 2023, the global immunoglobulin market is valued at approximately $10.5 billion, projected to grow at a compound annual growth rate (CAGR) of 8-10% through 2030 [1]. The United States accounts for roughly 50% of this market, driven by high prevalence of immunodeficiency disorders and established healthcare infrastructure.
Key Demand Drivers
- Increase in immunodeficiency diagnoses: Primary immunodeficiency (PID) affects about 1 in 1,200 to 2,000 individuals globally [2].
- Expanding approved indications: Autoimmune diseases like CIDP and ITP are increasingly recognized for immunoglobulin therapy.
- Growing awareness and diagnosis: Improved diagnostic protocols are expanding treated populations.
- Off-label use growth: Neurological and certain infectious diseases see rising off-label utilization.
Competitive landscape
Major brands include Gammagard (Baxter), Carimune (CSL Behring), and Privigen (Takeda). Generic or biosimilar entries are limited due to manufacturing complexities.
Pricing analysis
Historical pricing trends
Average wholesale prices (AWP) for intravenous immunoglobulin (IVIG) therapies have shown an upward trajectory over the past five years:
| Year |
Average Price per Gram (USD) |
Remarks |
| 2018 |
~$95 |
Initial steady pricing trend |
| 2020 |
~$125 |
Price increase driven by demand and manufacturing costs |
| 2022 |
~$145 |
Pandemic-related supply constraints |
Price factors
- Manufacturing complexity: Plasma sourcing, purification, and safety testing contribute (~50%) to costs.
- Supply chain: Plasma availability influences pricing, with shortages driving price surges.
- Regulatory environment: Stringent safety standards and FDA requirements increase production costs.
- Reimbursement policies: Medicare and private insurers negotiate discounts, influencing net prices.
Price projections
Projected increases suggest a compound annual growth rate (CAGR) of approximately 6-8%, based on current demand trends and costs:
| Year |
Predicted Price per Gram (USD) |
Basis for projection |
| 2025 |
~$165 |
Continued demand and production cost escalation |
| 2027 |
~$185 |
Market expansion and supply constraints |
| 2030 |
~$210 |
Increasing pressure from regulatory and safety standards |
Factors influencing future pricing
- Biosimilar entry: Potential for biosimilar immunoglobulins could pressure prices downward after 2025.
- Plasma supply dynamics: Increased plasma donations could stabilize costs, mitigating price ascents.
- Emerging therapies: Alternative treatments (e.g., monoclonal antibodies, gene therapy) may impact demand and pricing.
- Regulatory shifts: Changes in approval pathways or safety standards could alter manufacturing costs.
Regulatory and market access considerations
- FDA approvals: Expedited pathways for plasma-derived therapies depend on safety and efficacy data.
- Insurance coverage: Reimbursement dynamics affect net pricing; high-cost therapies may face coverage restrictions.
- Global access: Developing markets could see delayed adoption due to infrastructure and cost barriers.
Summary
NDC 72205-0146 (IVIG therapy) occupies a mature yet expanding segment in plasma-derived biologics. The global market's strong growth trends are driven by increased diagnoses and expanding indications. Price projections indicate continued escalation, moderated somewhat by biosimilar competition and plasma supply stability.
Key Takeaways
- The average price per gram for IVIG is forecasted to increase from approximately $145 in 2022 to $210 by 2030.
- Market growth is driven by rising immunodeficiency diagnoses, expanding indications, and supply chain dynamics.
- Biosimilars may exert downward pressure after 2025, but ongoing costs related to safety and manufacturing will sustain high prices.
- Price sensitivity varies by region, with the U.S. representing the largest and most profitable market segment.
- Regulatory, reimbursement, and supply factors remain critical in shaping future market prices.
FAQs
Q1: How does plasma donor availability affect IVIG pricing?
Plasma supply constraints increase production costs, leading to higher prices. Enhanced plasma collection efforts could stabilize costs.
Q2: Will biosimilars significantly reduce IVIG prices?
Potential biosimilar entrants after 2025 may lower prices. However, complex manufacturing and regulatory barriers may limit immediate impact.
Q3: Which indications are driving increased IVIG demand?
Immunodeficiency syndromes, autoimmune conditions like ITP, CIDP, and neurological disorders represent primary drivers.
Q4: How do regulatory standards influence IVIG pricing?
Stricter safety and quality standards raise manufacturing costs, raising prices unless offset by market competition or innovation.
Q5: What role does reimbursement policy play in future prices?
Reimbursement negotiations impact net prices; higher-cost therapies may face restrictions, influencing overall pricing strategies.
References
[1] MarketResearch.com. (2023). Global Immunoglobulin Market Outlook 2023-2030.
[2] Notarangelo, L. D. (2019). Primary immunodeficiencies. The New England Journal of Medicine, 381(17), 1648–1658.
[3] IQVIA. (2023). Pharmaceutical Pricing Trends.
